Nearly four in five pharmaceutical manufacturing professionals in India say open investigations are holding up drug batch releases, according to a white paper released in early November 2026. The finding matters well beyond the factory floor: a batch that cannot be released on time is a batch that does not reach the market — and for buyers of Indian generics, it is a direct signal about how much of a manufacturer’s quality system is spent chasing paperwork rather than preventing defects.
The white paper, The Compliance Spiral in Pharma Manufacturing, was produced by management consulting firm Vector Consulting Group and surveyed professionals at multiple mid- to large-scale, USFDA-approved formulation plants in India. It was reported by Livemint on 4 November 2026, Fortune India on 7 November 2026 and Medical Dialogues on 6 November 2026.
📋 What the White Paper Actually Found
Four survey statistics carry most of the story. Each is a self-reported figure from industry professionals, not an audited regulatory metric — an important distinction when using this data to judge any individual manufacturer.
- 80% of respondents said open investigations directly delayed batch release.
- Every surveyed plant had incidents awaiting closure, with some investigations taking as long as six months to resolve.
- 27% of senior leaders’ time was reported as going to managing investigation backlogs.
- 56% of reported production incidents were attributed to human error.
The mechanism is straightforward. In pharmaceutical manufacturing, a deviation during production must be investigated, documented and closed with corrective action before the affected batch can be released. When those investigations stack up, the release queue stalls — not because the batch failed a quality test, but because the file is still open.
🔍 Why Investigations Take So Long
The study is more interesting for what it says about why investigations drag on. Respondents did not primarily blame complex scientific problems. They blamed process friction:
- 83% reported multiple revisions to investigation drafts.
- 77% linked delayed evidence capture to information gaps.
- 73% said differences in functional priorities between departments contributed to delays or rework.
In other words, the quality system is being slowed by the way work is documented, reviewed and negotiated between teams — not by the difficulty of the science. That is a materially different diagnosis from “the plant has a quality problem,” and it changes what a fix looks like.
✍️ The Documentation and Supervision Load
Two operational data points contextualise the human-error figure. Operators were found to make an average of 120 entries in Batch Production Records (BPRs) per shift. Separately, 80% of supervisors oversee five or more production lines per shift.
That combination — heavy manual documentation plus thin supervision bandwidth — is the structural backdrop to the 56% human-error share. Errors rise, investigations multiply, and the same supervisors who must verify work are also the people signing off investigations. The white paper’s argument is that recurring incidents cannot be read purely as individual employee failures; the way production work is structured and supervised shapes how often incidents arise and how fast they close.
💡 What the Report Says Manufacturers Could Fix
The white paper proposes interventions on two fronts — reducing how many new incidents enter the system, and accelerating closure of the ones already open. Its stated projections:
- 30%–50% reduction in new incident generation.
- 20%–40% shorter closure timelines for existing investigations.
The recommended levers are unglamorous: capture evidence closer to the moment an incident occurs, simplify documentation, strengthen supervision ratios, and make investigation workflows easier to complete and review. Chandrachur Datta, Partner at Vector Consulting Group and co-author of the white paper, framed the test of a quality system as “not how much documentation it generates, but whether it helps prevent errors and resolve deviations without disrupting production,” adding that when underlying processes are hard to execute or verify, adding more checks may not address the root cause.
These are projections from the consulting firm behind the study, not independently verified outcomes.
🌍 Why This Matters for Buyers of Indian Generics
India is working toward a pharmaceutical industry ambition of $130 billion by 2030, and the surveyed plants were USFDA-approved formulation facilities — the same tier that supplies export markets and high-value generic portfolios. For buyers, importers and procurement teams, three practical implications follow.
- Release delays are not the same as quality failures. A batch held pending investigation closure has usually passed its analytical tests; the paperwork is incomplete. Do not read a delay as automatic evidence of a substandard product, but do ask what the open investigation was about.
- Ask about investigation closure metrics, not just certificates. A WHO-GMP certificate or a recent USFDA registration confirms the facility was inspected and found acceptable at a point in time. Metrics like median deviation closure time and the number of open incidents reveal how the system behaves between inspections.
- Recurring deviations deserve more scrutiny than isolated ones. The white paper’s core insight — that repeated incidents point to process design, not individual carelessness — applies equally to due diligence. A supplier whose deviations repeat in the same unit operation is telling you something structural.
For readers sourcing from Indian manufacturers, the practical due-diligence questions are documented in IMSDA’s verified member directory, which lists member distributors who can be checked for licensing and authorisation status before an order is placed.
⚠️ How to Read This Report Critically
Three caveats belong alongside the headline numbers. First, the survey population is professionals at mid- to large-scale USFDA-approved formulation plants — the compliance frontier, not the whole industry, so the findings say more about sophisticated plants than about small units in clusters such as Baddi or Ahmedabad. Second, the figures are self-reported perceptions from a consulting white paper, and the survey sample size was not stated in the coverage reviewed [CITATION NEEDED]. Third, the improvement projections (30%–50% and 20%–40%) are the consulting firm’s own estimates for its own proposed interventions.
None of that undermines the central point. An industry that intends to reach $130 billion by 2030 will get there faster by releasing batches on time than by adding another layer of checklists — and for buyers, a supplier that can close an investigation in weeks rather than six months is a materially safer bet than one that cannot.
Sources: Vector Consulting Group white paper “The Compliance Spiral in Pharma Manufacturing”, reported by Livemint (4 November 2026), Fortune India (7 November 2026) and Medical Dialogues (6 November 2026). Figures are as reported in those publications.
For more information, contact IMSDA at contact@indiamedicine.org.